0001564590-22-028593.txt : 20220809 0001564590-22-028593.hdr.sgml : 20220809 20220809080036 ACCESSION NUMBER: 0001564590-22-028593 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220809 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVANTA INC CENTRAL INDEX KEY: 0001076930 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 980110412 STATE OF INCORPORATION: A3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35083 FILM NUMBER: 221146460 BUSINESS ADDRESS: STREET 1: 125 MIDDLESEX TURNPIKE STREET 2: . CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-266-5618 MAIL ADDRESS: STREET 1: 125 MIDDLESEX TURNPIKE STREET 2: . CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: GSI GROUP INC DATE OF NAME CHANGE: 20050622 FORMER COMPANY: FORMER CONFORMED NAME: GSI LUMONICS INC DATE OF NAME CHANGE: 19990401 FORMER COMPANY: FORMER CONFORMED NAME: GSI LUMONICS DATE OF NAME CHANGE: 19990331 8-K 1 novt-8k_20220809.htm 8-K novt-8k_20220809.htm
false 0001076930 0001076930 2022-08-09 2022-08-09

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2022

 

NOVANTA INC.

(Exact name of registrant as specified in is charter)

 

 

New Brunswick, Canada

001-35083

98-0110412

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

125 Middlesex Turnpike

Bedford, Massachusetts

 

01730

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (781) 266-5700

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common shares, no par value

 

NOVT

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On August 9, 2022, Novanta Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended July 1, 2022. A copy of this press release is attached hereto as Exhibit 99.1.

The information contained in this Current Report, including Exhibit 99.1, is furnished under this Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing thereunder or under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

99.1

 

Press Release, dated August 9, 2022

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Novanta Inc.

 

 

 

 

Date: August 9, 2022

 

By:

/s/ Robert J. Buckley

 

 

 

Robert J. Buckley

 

 

 

Chief Financial Officer

 

 

 

 EX-99.1 2 novt-ex991_7.htm EX-99.1 novt-ex991_7.htm

 

 

FOR IMMEDIATE RELEASEExhibit 99.1
August 9, 2022

 

Novanta Announces Financial Results
for the Second Quarter 2022

 

•

Second Quarter 2022 GAAP Revenue increased 29% to $215 million

 

•

Second Quarter 2022 GAAP Consolidated Net Income of $17.5 million

 

•

Second Quarter 2022 GAAP Diluted Earnings Per Share increased 48% to $0.49

 

•

Second Quarter 2022 Adjusted Earnings Per Share increased 26% to $0.78

 

•

Second Quarter 2022 Adjusted EBITDA of $45.0 million

 

•

Raises Full Year Guidance

 

 

BEDFORD, Mass., August 9, 2022 -- Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2022.

 

Financial Highlights

Three Months Ended

 

(In millions, except per share amounts)

July 1,

 

 

July 2,

 

 

2022

 

 

2021

 

GAAP

 

 

 

 

 

 

 

Revenue

$

215.4

 

 

$

167.5

 

Operating Income

$

23.3

 

 

$

16.0

 

Consolidated Net Income

$

17.5

 

 

$

11.7

 

Diluted EPS

$

0.49

 

 

$

0.33

 

Non-GAAP*

 

 

 

 

 

 

 

Adjusted Operating Income

$

36.7

 

 

$

28.7

 

Adjusted Diluted EPS

$

0.78

 

 

$

0.62

 

Adjusted EBITDA

$

45.0

 

 

$

37.0

 

*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.

 

 

“Novanta achieved exceptionally strong financial results in the second quarter, with double-digit growth for sales, Adjusted EBITDA, and EPS,” said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. “Customer demand continues to be healthy across our medical and advanced industrial application areas, with bookings up 25% year over year, giving us a new record level of backlog at $653 million. The diversification of our portfolio is helping us to navigate through the ongoing macroeconomic environment difficulties, and we continue to expand in attractive application areas with outstanding progress in our design wins.”

 

 

Second Quarter

 

During the second quarter of 2022, Novanta generated GAAP revenue of $215.4 million, an increase of $47.8 million, or 28.6%, versus the second quarter of 2021. The Company’s acquisition activities resulted in an increase in revenue of $34.9 million, or 20.9%, compared to the second quarter of 2021. Changes in foreign currency exchange rates year over year adversely impacted our revenue by $8.6 million, or 5.2%, during the second quarter of 2022. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 12.9% for the second quarter of 2022 (see “Organic Revenue Growth” in the non-GAAP reconciliations below).

 

 

 

In the second quarter of 2022, GAAP operating income was $23.3 million, compared to $16.0 million in the second quarter of 2021. GAAP consolidated net income was $17.5 million in the second quarter of 2022, compared to $11.7 million in the second quarter of 2021. GAAP diluted earnings per share (“EPS”) was $0.49 in the second quarter of 2022, compared to $0.33 in the second quarter of 2021.

 

Adjusted Diluted EPS was $0.78 in the second quarter of 2022, compared to $0.62 in the second quarter of 2021. The Company ended the second quarter of 2022 with 35.9 million diluted weighted average shares outstanding. Adjusted EBITDA was $45.0 million in the second quarter of 2022, compared to $37.0 million in the second quarter of 2021.  

 

Operating cash flow for the second quarter of 2022 was $24.1 million. The Company completed the second quarter of 2022 with approximately $407.4 million of total debt and $100.5 million of total cash. Net Debt, as defined in the non-GAAP reconciliation below, was $312.3 million.

 

 

Financial Guidance

 

“Our strong first half performance gives us confidence to raise our outlook for the full year. For the third quarter, we expect to maintain momentum with strong double-digit revenue growth due to our consistently strong customer demand and record levels of backlog.” said Matthijs Glastra. “Our teams are working diligently to counteract the continued supply chain constraints, inflationary pressures, and foreign exchange challenges, yet we continue to see a strong full year, despite the macroeconomic environment.”

 

For the third quarter of 2022, the Company expects GAAP revenue of approximately $214 million to $216 million, demonstrating reported growth of 20% to 22%. The Company expects Adjusted Gross Profit Margin to be approximately 46.0%. The Company expects Adjusted EBITDA to be in the range of $43.5 million to $45.5 million and Adjusted Diluted EPS to be in the range of $0.71 to $0.76. The Company’s guidance assumes no significant changes in foreign exchange rates.

 

For the full year 2022, the Company expects GAAP revenue of approximately $848 million to $852 million, demonstrating reported growth of 20% to 21%. The Company expects Adjusted Gross Profit Margin to be approximately 46.0%. The Company expects Adjusted EBITDA to be in the range of $177 million to $180 million and Adjusted Diluted EPS to be in the range of $2.96 to $3.02. The Company’s guidance assumes no significant changes in foreign exchange rates.

 

Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance.  A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including future changes in the fair value of contingent considerations; significant discrete income tax expenses (benefits); divestitures and related expenses; acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; future restructuring expenses; foreign exchange gains/(losses); benefits or expenses associated with the completion of tax audits; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below.

 

Conference Call Information

 

The Company will host a conference call on Tuesday, August 9, 2022 at 10:00 a.m. ET to discuss these results and to provide a business update.  To access the call, please dial (888) 346-3959 prior to the scheduled conference call time.  Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.

 

 

 

 

A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Monday, October 3, 2022.

 

 

Use of Non-GAAP Financial Measures

 

The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income and Operating Margin, Adjusted Income before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Consolidated Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Consolidated Net Income, and Net Debt.

 

The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisition of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.

 

The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margins are used to determine bonus payments for senior management and employees. The Company also uses Adjusted Diluted EPS as a measurement for performance-based restricted stock units issued to certain executives. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.

 

Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

 

 

Safe Harbor and Forward-Looking Information

 

Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the third quarter and full year; statements regarding the COVID-19 pandemic; expectations for our end markets and market position; expectations regarding our ability to mitigate supply chain disruptions; inflationary pressures; expectations regarding the benefits of recent acquisitions; expectations regarding our design win and customer order activities and long-term prospects in our medical and advanced industrial end-markets; and other statements that are not historical facts.

 

 

 

 

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with the COVID-19 pandemic and other events outside our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; negative effects on global economic conditions, financial markets and our business as a result of the United Kingdom’s withdrawal from the European Union; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or delays in the delivery of our products; production difficulties and product delivery delays or disruptions; our exposure to medical device regulations, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign, U.S. federal, and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations affecting our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance policies and practices; our exposure to the credit risk of some of our customers and in weakened markets; our reliance on third party distribution channels; our reliance on original equipment manufacturer customers; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws, and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.

 

Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated by our future filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.

 

 

About Novanta

 

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision, and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

 

More information about Novanta is available on the Company’s website at www.novanta.com.  For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.

 

 

Novanta Inc.  

Investor Relations Contact:

Ray Nash

(781) 266-5137


 

 

 

 

 

NOVANTA INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars or shares, except per share amounts)

(Unaudited)

 

 

Three Months Ended

 

 

July 1,

 

 

July 2,

 

 

2022

 

 

2021

 

Revenue

$

215,356

 

 

$

167,523

 

Cost of revenue

 

120,111

 

 

 

95,117

 

Gross profit

 

95,245

 

 

 

72,406

 

Operating expenses:

 

 

 

 

 

 

 

Research and development and engineering

 

21,588

 

 

 

16,954

 

Selling, general and administrative

 

40,538

 

 

 

31,240

 

Amortization of purchased intangible assets

 

7,173

 

 

 

3,586

 

Restructuring, acquisition, and related costs

 

2,655

 

 

 

4,634

 

Total operating expenses

 

71,954

 

 

 

56,414

 

Operating income

 

23,291

 

 

 

15,992

 

Interest income (expense), net

 

(2,757

)

 

 

(1,378

)

Foreign exchange transaction gains (losses), net

 

152

 

 

 

(76

)

Other income (expense), net

 

68

 

 

 

(97

)

Income before income taxes

 

20,754

 

 

 

14,441

 

Income tax provision (benefit)

 

3,275

 

 

 

2,777

 

Consolidated net income

$

17,479

 

 

$

11,664

 

 

 

 

 

 

 

 

 

Earnings per common share:

 

 

 

 

 

 

 

Basic

$

0.49

 

 

$

0.33

 

Diluted

$

0.49

 

 

$

0.33

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding—basic

 

35,609

 

 

 

35,374

 

Weighted average common shares outstanding—diluted

 

35,933

 

 

 

35,763

 

 


 

 

 

NOVANTA INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars)

(Unaudited)

 

 

July 1,

 

 

December 31,

 

 

2022

 

 

2021

 

ASSETS

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

Cash and cash equivalents

$

100,489

 

 

$

117,393

 

Accounts receivable, net

 

129,808

 

 

 

115,617

 

Inventories

 

153,887

 

 

 

125,657

 

Prepaid expenses and other current assets

 

15,183

 

 

 

15,158

 

Total current assets

 

399,367

 

 

 

373,825

 

Property, plant and equipment, net

 

87,924

 

 

 

87,439

 

Operating lease assets

 

45,575

 

 

 

48,338

 

Intangible assets, net

 

193,499

 

 

 

220,989

 

Goodwill

 

466,411

 

 

 

479,500

 

Other assets

 

13,067

 

 

 

17,792

 

Total assets

$

1,205,843

 

 

$

1,227,883

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

Current portion of long-term debt

$

4,678

 

 

$

5,097

 

Accounts payable

 

77,351

 

 

 

68,514

 

Accrued expenses and other current liabilities

 

116,371

 

 

 

110,327

 

Total current liabilities

 

198,400

 

 

 

183,938

 

Long-term debt

 

402,679

 

 

 

429,361

 

Operating lease liabilities

 

42,580

 

 

 

45,700

 

Other long-term liabilities

 

30,015

 

 

 

47,593

 

Total liabilities

 

673,674

 

 

 

706,592

 

Stockholders’ Equity:

 

 

 

 

 

 

 

Total stockholders’ equity

 

532,169

 

 

 

521,291

 

Total liabilities and stockholders’ equity

$

1,205,843

 

 

$

1,227,883

 

 


 

 

 

NOVANTA INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(Unaudited)

 

 

Three Months Ended

 

 

July 1,

 

 

July 2,

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Consolidated net income

$

17,479

 

 

$

11,664

 

Adjustments to reconcile consolidated net income to

   net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

13,811

 

 

 

9,875

 

Share-based compensation

 

5,081

 

 

 

5,035

 

Deferred income taxes

 

(4,364

)

 

 

269

 

Other

 

3,017

 

 

 

1,638

 

Changes in assets and liabilities which (used)/provided cash,

    excluding effects from business acquisitions:

 

 

 

 

 

 

 

Accounts receivable

 

(8,678

)

 

 

248

 

Inventories

 

(18,581

)

 

 

(6,320

)

Other operating assets and liabilities

 

16,296

 

 

 

6,337

 

Net cash provided by (used in) operating activities

 

24,061

 

 

 

28,746

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Purchases of property, plant and equipment

 

(5,795

)

 

 

(5,375

)

Net cash provided by (used in) investing activities

 

(5,795

)

 

 

(5,375

)

Cash flows from financing activities:

 

 

 

 

 

 

 

Repayments under term loan and revolving credit facilities

 

(1,193

)

 

 

(1,361

)

Payments of debt issuance costs

 

(359

)

 

 

—

 

Payments of withholding taxes from share-based awards

 

(1,744

)

 

 

(156

)

Repurchases of common shares

 

(10,000

)

 

 

—

 

Payment of contingent consideration related to an acquisition

 

—

 

 

 

(1,401

)

Other financing activities

 

(148

)

 

 

(141

)

Net cash provided by (used in) financing activities

 

(13,444

)

 

 

(3,059

)

Effect of exchange rates on cash and cash equivalents

 

(3,138

)

 

 

(21

)

Increase (decrease) in cash and cash equivalents

 

1,684

 

 

 

20,291

 

Cash and cash equivalents, beginning of period

 

98,805

 

 

 

113,562

 

Cash and cash equivalents, end of period

$

100,489

 

 

$

133,853

 


 

 

 

NOVANTA INC.

Revenue by Reportable Segment

(In thousands of U.S. dollars)

(Unaudited)

 

 

Three Months Ended

 

 

July 1,

 

 

July 2,

 

 

2022

 

 

2021

 

Revenue

 

 

 

 

 

 

 

Photonics

$

69,461

 

 

$

62,357

 

Vision

 

65,516

 

 

 

63,447

 

Precision Motion

 

80,379

 

 

 

41,719

 

Total

$

215,356

 

 

$

167,523

 

 


 

 

 

NOVANTA INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(In thousands of U.S. dollars)

(Unaudited)

 

Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP):

 

Three Months Ended

 

 

July 1,

 

 

July 2,

 

 

2022

 

 

2021

 

Photonics

 

 

 

 

 

 

 

Gross Profit (GAAP)

$

31,182

 

 

$

29,593

 

Gross Profit Margin (GAAP)

 

44.9

%

 

 

47.5

%

Amortization of intangible assets

 

628

 

 

 

784

 

Acquisition fair value adjustments

 

—

 

 

 

—

 

Adjusted Gross Profit (Non-GAAP)

$

31,810

 

 

$

30,377

 

Adjusted Gross Profit Margin (Non-GAAP)

 

45.8

%

 

 

48.7

%

 

 

 

 

 

 

 

 

Vision

 

 

 

 

 

 

 

Gross Profit (GAAP)

$

26,535

 

 

$

24,443

 

Gross Profit Margin (GAAP)

 

40.5

%

 

 

38.5

%

Amortization of intangible assets

 

1,232

 

 

 

1,518

 

Acquisition fair value adjustments

 

—

 

 

 

—

 

Adjusted Gross Profit (Non-GAAP)

$

27,767

 

 

$

25,961

 

Adjusted Gross Profit Margin (Non-GAAP)

 

42.4

%

 

 

40.9

%

 

 

 

 

 

 

 

 

Precision Motion

 

 

 

 

 

 

 

Gross Profit (GAAP)

$

38,864

 

 

$

20,874

 

Gross Profit Margin (GAAP)

 

48.4

%

 

 

50.0

%

Amortization of intangible assets

 

1,476

 

 

 

680

 

Acquisition fair value adjustments

 

160

 

 

 

—

 

Adjusted Gross Profit (Non-GAAP)

$

40,500

 

 

$

21,554

 

Adjusted Gross Profit Margin (Non-GAAP)

 

50.4

%

 

 

51.7

%

 

 

 

 

 

 

 

 

Unallocated Corporate and Shared Services

 

 

 

 

 

 

 

Gross Profit (GAAP)

$

(1,336

)

 

$

(2,504

)

Amortization of intangible assets

 

—

 

 

 

—

 

Employee COVID-19 testing costs

 

39

 

 

 

1,473

 

Adjusted Gross Profit (Non-GAAP)

$

(1,297

)

 

$

(1,031

)

 

 

 

 

 

 

 

 

Novanta Inc.

 

 

 

 

 

 

 

Gross Profit (GAAP)

$

95,245

 

 

$

72,406

 

Gross Profit Margin (GAAP)

 

44.2

%

 

 

43.2

%

Amortization of intangible assets

 

3,336

 

 

 

2,982

 

Acquisition fair value adjustments

 

160

 

 

 

—

 

Employee COVID-19 testing costs

 

39

 

 

 

1,473

 

Adjusted Gross Profit (Non-GAAP)

$

98,780

 

 

$

76,861

 

Adjusted Gross Profit Margin (Non-GAAP)

 

45.9

%

 

 

45.9

%

 

 

 

 

NOVANTA INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Amounts in thousands except per share amounts)

(Unaudited)

 

Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):

 

Three Months Ended July 1, 2022

 

 

Operating Income

 

 

Operating Margin

 

 

Income before Income Taxes

 

 

Income Tax Provision / (Benefit)

 

 

Effective Tax Rate

 

 

Consolidated Net Income

 

 

Diluted EPS

 

GAAP results

$

23,291

 

 

 

10.8

%

 

$

20,754

 

 

$

3,275

 

 

 

15.8

%

 

$

17,479

 

 

$

0.49

 

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

10,509

 

 

 

4.9

%

 

 

10,509

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring costs

 

610

 

 

 

0.3

%

 

 

610

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition and related costs

 

2,045

 

 

 

0.9

%

 

 

2,045

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition inventory fair value adjustments

 

160

 

 

 

0.1

%

 

 

160

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee COVID-19 testing costs

 

39

 

 

 

0.0

%

 

 

39

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign exchange transaction (gains) losses, net

 

 

 

 

 

 

 

 

 

(152

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax effect on non-GAAP adjustments

 

 

 

 

 

 

 

 

 

 

 

 

 

2,673

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP tax adjustments

 

 

 

 

 

 

 

 

 

 

 

 

 

81

 

 

 

 

 

 

 

 

 

 

 

 

 

Total non-GAAP adjustments

 

13,363

 

 

 

6.2

%

 

 

13,211

 

 

 

2,754

 

 

 

 

 

 

 

10,457

 

 

 

0.29

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted results (Non-GAAP)

$

36,654

 

 

 

17.0

%

 

$

33,965

 

 

$

6,029

 

 

 

17.8

%

 

$

27,936

 

 

$

0.78

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - Diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

35,933

 


 

 

 

NOVANTA INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Amounts in thousands except per share amounts)

(Unaudited)

 

Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):

 

Three Months Ended July 2, 2021

 

 

Operating Income

 

 

Operating Margin

 

 

Income before Income Taxes

 

 

Income Tax Provision / (Benefit)

 

 

Effective Tax Rate

 

 

Consolidated Net Income

 

 

Diluted EPS

 

GAAP results

$

15,992

 

 

 

9.5

%

 

$

14,441

 

 

$

2,777

 

 

 

19.2

%

 

$

11,664

 

 

$

0.33

 

Non-GAAP Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

6,568

 

 

 

3.9

%

 

 

6,568

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring costs

 

1,165

 

 

 

0.7

%

 

 

1,165

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition and related costs

 

3,469

 

 

 

2.1

%

 

 

3,469

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee COVID-19 testing costs

 

1,473

 

 

 

0.9

%

 

 

1,473

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign exchange transaction (gains) losses, net

 

 

 

 

 

 

 

 

 

76

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax effect on non-GAAP adjustments

 

 

 

 

 

 

 

 

 

 

 

 

 

2,518

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP tax adjustments

 

 

 

 

 

 

 

 

 

 

 

 

 

(347

)

 

 

 

 

 

 

 

 

 

 

 

 

Total non-GAAP adjustments

 

12,675

 

 

 

7.6

%

 

 

12,751

 

 

 

2,171

 

 

 

 

 

 

 

10,580

 

 

 

0.29

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted results (Non-GAAP)

$

28,667

 

 

 

17.1

%

 

$

27,192

 

 

$

4,948

 

 

 

18.2

%

 

$

22,244

 

 

$

0.62

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - Diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

35,763

 

 

 

 

 

 

 

NOVANTA INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(In thousands of U.S. dollars)

(Unaudited)

 

   Adjusted EBITDA (Non-GAAP):

 

Three Months Ended

 

 

July 1,

 

 

July 2,

 

 

2022

 

 

2021

 

Consolidated Net Income (GAAP)

$

17,479

 

 

$

11,664

 

Consolidated Net Income Margin

 

8.1

%

 

 

7.0

%

Interest (income) expense, net

 

2,757

 

 

 

1,378

 

Income tax provision (benefit)

 

3,275

 

 

 

2,777

 

Depreciation and amortization

 

13,811

 

 

 

9,875

 

Share-based compensation

 

5,081

 

 

 

5,035

 

Restructuring, acquisition, and related costs

 

2,655

 

 

 

4,634

 

Acquisition fair value adjustment

 

160

 

 

 

-

 

Employee COVID-19 testing costs

 

39

 

 

 

1,473

 

Other, net

 

(220

)

 

 

173

 

Adjusted EBITDA (Non-GAAP)

$

45,037

 

 

$

37,009

 

Adjusted EBITDA Margin (Non-GAAP)

 

20.9

%

 

 

22.1

%

 

 

Organic Revenue Growth (Non-GAAP):

 

Three Months Ended July 1, 2022

 

 

Compared to

 

 

Three Months Ended July 2, 2021

 

Reported Revenue Growth/(Decline) (GAAP)

 

28.6

%

Less: Change attributable to acquisitions

 

20.9

%

Plus: Change due to foreign currency

 

5.2

%

Organic Revenue Growth/(Decline) (Non-GAAP)

 

12.9

%

 

 

Net Debt (Non-GAAP):

 

July 1,

 

 

December 31,

 

 

2022

 

 

2021

 

Total Debt (GAAP)

$

407,357

 

 

$

434,458

 

Plus: Deferred financing costs

 

5,436

 

 

 

4,126

 

Gross Debt

 

412,793

 

 

 

438,584

 

Less: Cash and cash equivalents

 

(100,489

)

 

 

(117,393

)

Net Debt (Non-GAAP)

$

312,304

 

 

$

321,191

 

 

 

Free Cash Flow (Non-GAAP):

 

Three Months Ended

 

 

July 1,

 

 

July 2,

 

 

2022

 

 

2021

 

Net Cash Provided by Operating Activities (GAAP)

$

24,061

 

 

$

28,746

 

Less: Purchases of property, plant and equipment

 

(5,795

)

 

 

(5,375

)

Plus: Proceeds from sale of property, plant and equipment

 

—

 

 

 

—

 

Free Cash Flow (Non-GAAP)

$

18,266

 

 

$

23,371

 

Consolidated Net Income (GAAP)

$

17,479

 

 

$

11,664

 

Net Cash Provided by Operating Activities as a Percentage of Consolidated Net Income

 

137.7

%

 

 

246.5

%

Free Cash Flow as a Percentage of Consolidated Net Income

 

104.5

%

 

 

200.4

%

 


 

 

 

Non-GAAP Financial Measures

 

Organic Revenue Growth

 

The Company defines the term “organic revenue” as revenue excluding the impact from business acquisitions, divestitures, product line discontinuations, and the effect of foreign currency translation. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing current period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that this non-GAAP financial measure, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of foreign currency translation from these measures because foreign currency translation is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because these activities can vary dramatically between reporting periods and between the Company and its peers, which the Company believes makes comparisons of long-term performance trends difficult for management and investors. Organic Revenue Growth is also used as a performance metric to determine bonus payments for senior management and employees.

 

Adjusted Gross Profit and Adjusted Gross Profit Margin

 

The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin is displayed in the tables above. Adjusted Gross Profit and Adjusted Gross Profit Margin exclude amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions because: (1) the amounts are non-cash; (2) the Company cannot influence the timing and amount of future expense recognition; and (3) excluding such expenses provides investors and management better visibility into the underlying trend and performance of our businesses. Additionally, the Company excluded costs directly related to employee COVID-19 testing as these costs are unique to the COVID-19 pandemic and have had a significant impact on the Company’s operating results.

 

Adjusted Operating Income and Adjusted Operating Margin

 

The calculation of Adjusted Operating Income and Adjusted Operating Margin is displayed in the tables above. Adjusted Operating Income and Adjusted Operating Margin exclude amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, and costs directly related to employee COVID-19 testing for the reasons described for Adjusted Gross Profit and Adjusted Gross Profit Margin above. The Company also excluded restructuring, acquisition, and related costs due to the significant changes that have occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”

 

Adjusted Income before Income Taxes

 

The calculation of Adjusted Income before Income Taxes is displayed in the tables above.  The calculation of Adjusted Income before Income Taxes excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, and restructuring, acquisition and related costs for the reasons described for Adjusted Operating Income and Adjusted Operating Margin above. The Company excludes write-off of unamortized deferred financing costs because they only arise in certain specific situations when the Company’s existing credit agreement is terminated or modified. The Company also excluded foreign exchange transaction gains (losses) from the calculation of Adjusted Income before Income Taxes as the Company cannot fully influence the timing and amount of foreign exchange transaction gains (losses).

 

Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate

 

The Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated based on the Adjusted Income before Income Taxes by jurisdiction and the applicable tax rates currently in effect for the respective jurisdictions. In addition, the Company excluded significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of

 

 

acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments discussed above.

 

Adjusted Consolidated Net Income

 

The calculation of Adjusted Consolidated Net Income is displayed in the tables above.  Because income before income taxes is included in determining Consolidated Net Income, the calculation of Adjusted Consolidated Net Income also excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, write-off of unamortized deferred financing costs, and foreign exchange transaction gains (losses) for the reasons described for Adjusted Income before Income Taxes. In addition, the Company excluded significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments discussed above.

 

Adjusted Diluted EPS

 

The calculation of Adjusted Diluted EPS is displayed in the tables above.  Because Consolidated Net Income is used in the calculation of diluted EPS, Adjusted Diluted EPS excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, write-off of unamortized deferred financing costs, foreign exchange transaction gains (losses), significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments for the reasons described above for Adjusted Consolidated Net Income.

 

Adjusted EBITDA and Adjusted EBITDA Margin

 

The Company defines Adjusted EBITDA as the income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, acquisition fair value adjustments, other non-operating (income) expense items, including foreign exchange transaction (gains) losses, write-off of unamortized deferred financing costs, and net periodic pension costs of the Company’s frozen U.K. defined benefit pension plan for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”

 

Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.

 

In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future the Company may incur expenses that are the same as, or similar to, some of the adjustments in this presentation.

 

Free Cash Flow and Free Cash Flow as a Percentage of Consolidated Net Income

 

The Company defines Free Cash Flow as net cash provided by operating activities less cash paid for purchases of property, plant and equipment and plus cash proceeds from sales of property, plant and equipment. Free Cash Flow as a Percentage of Consolidated Net Income is defined as Free Cash Flow divided by Consolidated Net Income.  Management believes these non-GAAP financial measures are important indicators of the Company’s liquidity as well as its ability to service its outstanding debt and to fund future growth.  

 

Net Debt

 

The Company defines Net Debt as its total debt as reported on the consolidated balance sheet plus unamortized deferred financing costs and less its cash and cash equivalents as of the end of the period presented. Management uses Net Debt to monitor the Company’s outstanding debt obligations that could not be satisfied by its cash and cash equivalents on hand.

 

* * * *

 EX-101.SCH 3 novt-20220809.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 novt-20220809_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 novt-20220809_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 09, 2022
Entity Registrant Name NOVANTA INC.
Entity Central Index Key 0001076930
Entity Emerging Growth Company false
Entity File Number 001-35083
Entity Incorporation, State or Country Code A3
Entity Tax Identification Number 98-0110412
Entity Address, Address Line One 125 Middlesex Turnpike
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code 781
Local Phone Number 266-5700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares, no par value
Trading Symbol NOVT
Security Exchange Name NASDAQ
XML 7 novt-8k_20220809_htm.xml IDEA: XBRL DOCUMENT 0001076930 2022-08-09 2022-08-09 false 0001076930 8-K 2022-08-09 NOVANTA INC. A3 001-35083 98-0110412 125 Middlesex Turnpike Bedford MA 01730 781 266-5700 false false false false Common shares, no par value NOVT NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports novt-8k_20220809.htm novt-20220809.xsd novt-20220809_lab.xml novt-20220809_pre.xml novt-ex991_7.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "novt-8k_20220809.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "novt-8k_20220809.htm" ] }, "labelLink": { "local": [ "novt-20220809_lab.xml" ] }, "presentationLink": { "local": [ "novt-20220809_pre.xml" ] }, "schema": { "local": [ "novt-20220809.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "novt", "nsuri": "http://www.novanta.com/20220809", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "novt-8k_20220809.htm", "contextRef": "C_0001076930_20220809_20220809", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "novt-8k_20220809.htm", "contextRef": "C_0001076930_20220809_20220809", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.novanta.com/20220809/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-22-028593-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-028593-xbrl.zip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